Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AXETIL versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AXETIL versus ROCEPHIN.
CEFUROXIME AXETIL vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime axetil is a prodrug that is hydrolyzed to cefuroxime, a second-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
250–500 mg orally twice daily; for severe infections (e.g., pneumonia), 500 mg twice daily; for uncomplicated urinary tract infections, 250 mg twice daily; for Lyme disease, 500 mg twice daily for 20 days.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
1.2-1.6 hours (normal renal function); prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min). For oral cefuroxime axetil, consider absorption and conversion to active cefuroxime.
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Renal: 70-90% unchanged by glomerular filtration and tubular secretion; biliary/fecal: <10%
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic